Functionalized liposomes for targeted breast cancer drug delivery.

Fiche publication

Date publication

juin 2023

Journal

Bioactive materials

Auteurs

Membres identifiés du Cancéropôle Est :
Dr FRANCIUS Grégory , Pr GRANDEMANGE Stéphanie

Tous les auteurs :
Nel J, Elkhoury K, Velot É, Bianchi A, Acherar S, Francius G, Tamayol A, Grandemange S, Arab-Tehrany E

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/36632508

Résumé

Despite the exceptional progress in breast cancer pathogenesis, prognosis, diagnosis, and treatment strategies, it remains a prominent cause of female mortality worldwide. Additionally, although chemotherapies are effective, they are associated with critical limitations, most notably their lack of specificity resulting in systemic toxicity and the eventual development of multi-drug resistance (MDR) cancer cells. Liposomes have proven to be an invaluable drug delivery system but of the multitudes of liposomal systems developed every year only a few have been approved for clinical use, none of which employ active targeting. In this review, we summarize the most recent strategies in development for actively targeted liposomal drug delivery systems for surface, transmembrane and internal cell receptors, enzymes, direct cell targeting and dual-targeting of breast cancer and breast cancer-associated cells, e.g., cancer stem cells, cells associated with the tumor microenvironment, etc.